Last reviewed 2026-04-22 · How we verify

Antibiotics, cefuroxime and metronidazole

Antibiotics, cefuroxime and metronidazole is a Beta-lactam antibiotic + nitroimidazole antibiotic combination Small molecule drug developed by Helsinki University Central Hospital. It is currently FDA-approved for Surgical site infection prophylaxis, Mixed aerobic-anaerobic bacterial infections, Intra-abdominal infections.

Cefuroxime inhibits bacterial cell wall synthesis while metronidazole disrupts anaerobic bacterial DNA, together providing broad-spectrum coverage against aerobic and anaerobic pathogens.

Cefuroxime inhibits bacterial cell wall synthesis while metronidazole disrupts anaerobic bacterial DNA, together providing broad-spectrum coverage against aerobic and anaerobic pathogens. Used for Surgical site infection prophylaxis, Mixed aerobic-anaerobic bacterial infections, Intra-abdominal infections.

At a glance

Mechanism of action

Cefuroxime is a second-generation cephalosporin that binds penicillin-binding proteins and inhibits peptidoglycan cross-linking in bacterial cell walls, leading to cell lysis. Metronidazole is a nitroimidazole that generates reactive intermediates in anaerobic organisms, causing DNA strand breaks and cell death. This combination targets both aerobic gram-negative and gram-positive bacteria as well as anaerobes, commonly used for surgical prophylaxis and mixed infections.

Approved indications

• Surgical site infection prophylaxis
• Mixed aerobic-anaerobic bacterial infections
• Intra-abdominal infections
• Gynecological infections

Common side effects

• Diarrhea
• Nausea
• Hypersensitivity reactions (cefuroxime)
• Metallic taste (metronidazole)
• Headache

Key clinical trials

• Standard Versus Prolonged Antibiotic Prophylaxis After Pancreatoduodenectomy (SPARROW) (PHASE4)
• Per Oral Versus Intravenous Postoperative Antibiotics After Surgery for Complicated Appendicitis. (NA)
• Identification of the Optimal Treatment Strategy for Complex Appendicitis in the Pediatric Population
• Role of Delay and Antibiotics on Perforation Rate While Waiting Appendectomy (PHASE4)
• The Comparison of Outcomes of Antibiotic Drugs and Appendectomy (CODA) Trial (NA)
• Short-Term Use of Antibiotics and Adherence Level (NA)
• Patients Response to Early Switch To Oral:Osteomyelitis Study (EARLY_PHASE1)
• Conservative Versus Operative ManageMent of Acute Uncomplicated Appendicitis (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Antibiotics, cefuroxime and metronidazole CI brief — competitive landscape report
• Antibiotics, cefuroxime and metronidazole updates RSS · CI watch RSS
• Helsinki University Central Hospital portfolio CI

Frequently asked questions about Antibiotics, cefuroxime and metronidazole

Related

• Drug class: All Beta-lactam antibiotic + nitroimidazole antibiotic combination drugs
• Target: All drugs targeting Bacterial penicillin-binding proteins (cefuroxime); anaerobic bacterial DNA (metronidazole)
• Manufacturer: Helsinki University Central Hospital — full pipeline
• Therapeutic area: All drugs in Infectious Disease
• Indication: Drugs for Surgical site infection prophylaxis
• Indication: Drugs for Mixed aerobic-anaerobic bacterial infections
• Indication: Drugs for Intra-abdominal infections
• Compare: Antibiotics, cefuroxime and metronidazole vs similar drugs
• Pricing: Antibiotics, cefuroxime and metronidazole cost, discount & access